<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3AAntihypertensive_drug%2F12%2Fen</id>
	<title>Translations:Antihypertensive drug/12/en - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tiffa.net/w/index.php?action=history&amp;feed=atom&amp;title=Translations%3AAntihypertensive_drug%2F12%2Fen"/>
	<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/12/en&amp;action=history"/>
	<updated>2026-05-28T02:55:05Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.0</generator>
	<entry>
		<id>https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/12/en&amp;diff=74524&amp;oldid=prev</id>
		<title>FuzzyBot: Importing a new version from external source</title>
		<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/12/en&amp;diff=74524&amp;oldid=prev"/>
		<updated>2023-11-03T23:24:35Z</updated>

		<summary type="html">&lt;p&gt;Importing a new version from external source&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 08:24, 4 November 2023&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l11&quot;&gt;Line 11:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 11:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[valsartan]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[valsartan]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Fimasartan]]&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;* [[Fimasartan]]&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.&lt;del style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;{{citation needed|date=July 2019}}&lt;/del&gt;&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>FuzzyBot</name></author>
	</entry>
	<entry>
		<id>https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/12/en&amp;diff=72922&amp;oldid=prev</id>
		<title>FuzzyBot: Importing a new version from external source</title>
		<link rel="alternate" type="text/html" href="https://wiki.tiffa.net/w/index.php?title=Translations:Antihypertensive_drug/12/en&amp;diff=72922&amp;oldid=prev"/>
		<updated>2023-10-20T03:55:52Z</updated>

		<summary type="html">&lt;p&gt;Importing a new version from external source&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Angiotensin II receptor antagonists==&lt;br /&gt;
[[File:Valsartan.svg|thumb|[[Valsartan]], an angiotensin II receptor antagonist]]&lt;br /&gt;
[[Angiotensin II receptor antagonist]]s work by [[receptor antagonist|antagonizing]] the activation of [[angiotensin receptor]]s.&lt;br /&gt;
* [[azilsartan]]&lt;br /&gt;
* [[candesartan]]&lt;br /&gt;
* [[eprosartan]]&lt;br /&gt;
* [[irbesartan]]&lt;br /&gt;
* [[losartan]]&lt;br /&gt;
* [[olmesartan]]&lt;br /&gt;
* [[telmisartan]]&lt;br /&gt;
* [[valsartan]]&lt;br /&gt;
* [[Fimasartan]]&lt;br /&gt;
In 2004, an article in the [[BMJ]] examined the evidence for and against the suggestion that angiotensin receptor blockers may increase the risk of [[myocardial infarction]] (heart attack). The matter was debated in 2006 in the medical journal of the [[American Heart Association]]. There is no consensus on whether ARBs have a tendency to increase MI, but there is also no substantive evidence to indicate that ARBs are able to reduce MI.{{citation needed|date=July 2019}}&lt;/div&gt;</summary>
		<author><name>FuzzyBot</name></author>
	</entry>
</feed>